Literature DB >> 17962422

Drug interaction studies of therapeutic proteins or monoclonal antibodies.

Iftekhar Mahmood1, Martin David Green.   

Abstract

Drug interactions can alter the pharmacokinetics and/or pharmacodynamics of a drug. In pharmacokinetic drug interactions, the concentrations of 1 or more drugs are altered by another. This change in concentration in a given drug may be due to changes in absorption, distribution, metabolism, or elimination. The pharmacodynamic interaction can lead to additive, synergistic, or antagonistic effects of a drug. Drug interaction studies are regularly conducted with conventional drugs (small molecules), but very few drug interaction studies have been performed with macromolecules (therapeutic proteins or monoclonal antibodies). This is mainly because most macromolecules are not metabolized by the cytochrome P450 system, and their mechanism of elimination is complex. However, it has been shown in several studies that interferons can have an impact on the cytochrome P450 system that may alter the pharmacokinetics and pharmacodynamics of a conventional drug when given with interferons. Therefore, it is important to evaluate the effect of other classes of macromolecules (cytokines, interleukins, monoclonal antibodies) on drug-metabolizing enzymes. It is also imperative that the effects of conventional drugs on the pharmacokinetics and pharmacodynamics of macromolecules be conducted. The present review encompasses several drug interaction studies that were conducted with macromolecules and highlights the impact of these studies on the pharmacokinetics and/or pharmacodynamics of the involved drugs.

Mesh:

Substances:

Year:  2007        PMID: 17962422     DOI: 10.1177/0091270007308616

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  11 in total

Review 1.  Impact of infectious and inflammatory disease on cytochrome P450-mediated drug metabolism and pharmacokinetics.

Authors:  E T Morgan
Journal:  Clin Pharmacol Ther       Date:  2009-02-11       Impact factor: 6.875

Review 2.  CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications.

Authors:  Jang-Ik Lee; Lei Zhang; Angela Y Men; Leslie A Kenna; Shiew-Mei Huang
Journal:  Clin Pharmacokinet       Date:  2010-05       Impact factor: 6.447

Review 3.  Regulation of drug-metabolizing enzymes in infectious and inflammatory disease: implications for biologics-small molecule drug interactions.

Authors:  Pankajini Mallick; Guncha Taneja; Bhagavatula Moorthy; Romi Ghose
Journal:  Expert Opin Drug Metab Toxicol       Date:  2017-02-22       Impact factor: 4.481

Review 4.  Update on Therapeutic Protein-Drug Interaction: Information in Labeling.

Authors:  Xing Jing; Ping Ji; Sarah J Schrieber; Elimika P Fletcher; Chandrahas Sahajwalla
Journal:  Clin Pharmacokinet       Date:  2020-01       Impact factor: 6.447

5.  Pharmacokinetic mAb-mAb interaction: anti-VEGF mAb decreases the distribution of anti-CEA mAb into colorectal tumor xenografts.

Authors:  Lubna Abuqayyas; Joseph P Balthasar
Journal:  AAPS J       Date:  2012-04-18       Impact factor: 4.009

6.  CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.

Authors:  Tae H Han; Ajay K Gopal; Radhakrishnan Ramchandren; Andre Goy; Robert Chen; Jeffrey V Matous; Maureen Cooper; Laurie E Grove; Stephen C Alley; Carmel M Lynch; Owen A O'Connor
Journal:  J Clin Pharmacol       Date:  2013-06-10       Impact factor: 3.126

7.  AAPS workshop report: strategies to address therapeutic protein-drug interactions during clinical development.

Authors:  Sandhya Girish; Steven W Martin; Mark C Peterson; Lei K Zhang; Hong Zhao; Joseph Balthasar; Raymond Evers; Honghui Zhou; Min Zhu; Lewis Klunk; Chao Han; Eva Gil Berglund; Shiew-Mei Huang; Amita Joshi
Journal:  AAPS J       Date:  2011-06-01       Impact factor: 4.009

8.  In vitro evaluation of the effects of 4-aminopyridine on cytochrome P450 enzymes.

Authors:  Anthony Caggiano; Andrew Blight
Journal:  J Drug Assess       Date:  2013-03-26

Review 9.  Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Peptides: When Is the Assessment of Certain Factors Warranted?

Authors:  Iftekhar Mahmood; Mark Pettinato
Journal:  Antibodies (Basel)       Date:  2021-12-21

10.  Time-Resolved Effect of Interferon-Alpha 2a on Activities of Nuclear Factor Kappa B, Pregnane X Receptor and on Drug Disposition Genes.

Authors:  Dirk Theile; Lelia Wagner; Cindy Bay; Walter Emil Haefeli; Johanna Weiss
Journal:  Pharmaceutics       Date:  2021-05-28       Impact factor: 6.321

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.